Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Hodgkin Disease 11Neoplasms 2Mycosis Fungoides 2Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Mesothelioma, Malignant 1Melanoma 1Lymphomatoid Papulosis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 65Nivolumab 56Ipilimumab 34Specimen Handling 23Magnetic Resonance Spectroscopy 21Cyclophosphamide 17Biopsy 13Radiosurgery 12relatlimab 11fludarabine 11binimetinib 11Opdualag 11CTLA-4 Antigen 11trametinib 10fludarabine phosphate 8dabrafenib 8lifileucel 7encorafenib 7aldesleukin 7atezolizumab 6Interleukin-2 6cemiplimab 5X-Rays 5Paclitaxel 5Immunoglobulin G 5Blood Specimen Collection 5Taxes 4Radiotherapy 4Pemetrexed 4Gemcitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Brentuximab Vedotin × 90 days × Clear all
NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Seagen Inc.

Phase 2 Completed
161 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡